Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Recurrence × Dosage Forms × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 3 Leukemia 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Stomach Neoplasms 1 Solid Tumors 1 Recurrence 1 Prostatic Neoplasms 1 Neurofibromatosis 1 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Advanced Solid Tumors 1

Interventions

Dexamethasone 63 Lenalidomide 34 Cyclophosphamide 33 pomalidomide 32 Rituximab 31 Bortezomib 28 venetoclax 27 fludarabine 26 Gemcitabine 21 carfilzomib 20 Paclitaxel 19 pembrolizumab 16 daratumumab 16 Cisplatin 16 Carboplatin 15 Calcium Dobesilate 14 Azacitidine 14 ibrutinib 12 Nivolumab 12 Docetaxel 12 Cytarabine 12 obinutuzumab 11 durvalumab 10 Doxorubicin 10 Bevacizumab 10 tisagenlecleucel 9 blinatumomab 9 Injections 9 Cetuximab 9 Bendamustine Hydrochloride 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02939183 2024-09-26

INTREPID-1

Amgen

Phase 1 Completed

61 enrolled 28 charts

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡